Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance
Although there is no direct evidence, we support the following conclusions: saPs may be used to treat ICI-Ps without an appreciable loss of ICI effectiveness. Generally, it is not necessary to interrupt ICI therapy. When available, non-steroid saPs are preferred over systemic corticosteroids for the treatment of psoriasis.
Authors
- Kim Papp (ORCID: https://orcid.org/0000-0001-9557-3642)
- Rosalyn A. Juergens (ORCID: https://orcid.org/0000-0001-8627-4704)
- Joël Claveau
- Jennifer Beecker (ORCID: https://orcid.org/0000-0003-0872-3388)
- L. Puig (ORCID: https://orcid.org/0000-0001-6083-0952)
- Jan Dutz (ORCID: https://orcid.org/0000-0003-3035-0522)
- Stephanie Snow (ORCID: https://orcid.org/0000-0003-3847-0289)
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Sandeep R. Sehdev (ORCID: https://orcid.org/0000-0001-7434-2263)
- Maxwell Benjamin Sauder (ORCID: https://orcid.org/0000-0002-5605-3844)
- V. Sibaud (ORCID: https://orcid.org/0000-0003-2585-6633)
- Barbara Melosky (ORCID: https://orcid.org/0000-0003-2865-659X)
- Anisha B. Patel (ORCID: https://orcid.org/0000-0002-5372-784X)
- Noah I. Hornick (ORCID: https://orcid.org/0000-0002-3503-7693)
- Vinod Chandran (ORCID: https://orcid.org/0000-0002-8297-0275)
Institutions
- Universitat Autònoma de Barcelona (ES)
- BC Cancer Agency (CA)
- Dalhousie University (CA)
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- University of British Columbia (CA)
- University of Ottawa (CA)
- Oregon Health & Science University (US)
- University of Toronto (CA)
- Juravinski Cancer Centre (CA)
- Ottawa Hospital (CA)
- Hospital de Sant Pau (ES)
- Villa Maria Hospital (UG)
- Vancouver General Hospital (CA)
- Research Canada (CA)
- MedSIR (Spain) (ES)
- Hôtel-Dieu de Québec (CA)
- Probity Medical Research (CA)
- Institut Claudius Regaud (FR)
- Krembil Foundation (CA)
- Blackberry (Canada) (CA)
- BC Children's Hospital (CA)
- International Breast Cancer Study Group (CH)
- The University of Texas Health Science Center (US)
- Institut de Recerca Sant Pau (ES)
- Krembil Research Institute
- Ottawa Hospital Research Institute (CA)
- Universidad Europea de Madrid (ES)
- The University of Texas Health Science Center at Houston (US)
- McMaster University (CA)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1111/jdv.20809
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- L'Oreal USA
- Melanoma Research Alliance
- Gilead Sciences
- Ariad Pharmaceuticals
- Celgene
- Therakos
- Queen Mary University of London
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- BC Children's Hospital
- Les Laboratories Pierre Fabre
- Clovis Oncology
- BeiGene
- Incyte
- MacroGenics
- Seagen
- Eisai
- Astellas Pharma
- Galderma
- Servier
- Sun Pharma
- Bausch Health
- LEO Pharma
- National Institutes of Health
- Samsung
- EMD Serono
- University of Texas MD Anderson Cancer Center
- Novartis Pharmaceuticals Canada
- Amgen Canada
- Sanofi Genzyme
- Eli Lilly Canada
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Center for Advancing Translational Sciences
- Janssen Pharmaceuticals
- Janssen Canada
- Daiichi Sankyo Europe